Health Condition 1: null- Veeucae (Viral Warts)
Conditions
Interventions
Intervention1: Candida skin test antigen:: Credisol (Manufactured by creative drug industries, Mumbai)
Intervention2: BCG vaccine: Tubervac available commercially
Intervention3: MMR vaccine: The vaccc
Sponsors
Dr Aayush Gupta
Eligibility
Inclusion criteria
Inclusion criteria: Males or females more than 13 years of age presenting with multiple non genital warts. The diagnosis of warts confirmed clinically
Exclusion criteria
Exclusion criteria: Age History of prior allergic response to mumps, BCG or Candida antigen. Pregnancy Lactation HIV infection Iatrogenic immunosuppression Primary immunosuppression Acute febrile illness Subjects who received any other treatments for their warts in the last month before enrolment Past history of asthma or allergic skin disorders Past history of meningitis or convulsions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical resolution of mother and distant wart in response to intralesional immunotherapy.Timepoint: 6 months after first injection | — |
Secondary
| Measure | Time frame |
|---|---|
| Appearance of side effects due to intralesional immunotherapy Timepoint: 2, 4 , 6 ,8 and 12 weeks;Partial resolution of mother and distant wartsTimepoint: 2, 4, 6, 8 and 12 weeks | — |
Countries
India
Contacts
Public ContactDr Aayush Gupta
Dr. D.Y. Patil Medical College, Pune
Outcome results
None listed